Home World News FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma World News FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 815 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Καρκίνος οισοφάγου January 22, 2019 Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... February 13, 2022 Bus Driver Wears Different Costume Each Day To Make Kids Smile... January 27, 2022 Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients... April 7, 2025 Load more HOT NEWS Study Offers Insights on Health Problems among AYA Cancer Survivors Breaking News: Medical Debt and Your Credit Report Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer Peace